Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L H Chen

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Stroke|October 6, 2023
Advances in Stroke: Brain Health in 2023Tatjana Rundek, Christopher L H Chen
Stroke|September 14, 2021
Vascular Brain HealthChristopher L H Chen, Tatjana Rundek
Cerebrovascular Diseases (Basel, Switzerland)|March 4, 2020
Frequency and Clinical Impact of Serious Adverse Events on Post-Stroke Recovery with NeuroAiD (MLC601) versus Placebo: The CHInese Medicine Neuroaid Efficacy on Stroke Recovery StudyNarayanaswamy Venketasubramanian, Rajesh B Moorakonda, Qingshu Lu, et al.
Stroke|December 3, 2015
Comparison Between the Original and Shortened Versions of the National Institutes of Health Stroke Scale in Ischemic Stroke Patients of Intermediate SeverityChun Fan Lee, Narayanaswamy Venketasubramanian, K S Lawrence Wong, et al.
Journal of the American Medical Directors Association|May 24, 2020
Psychometric Properties of the National Institute of Neurological Disorders and Stroke and Canadian Stroke Network Neuropsychological Battery in an Asian Older Adult SampleKimberly A Chew, Eddie J Y Chong, Christopher L H Chen, et al.
Journal of Evidence-Based Medicine|August 21, 2015
The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD)Narayanaswamy Venketasubramanian, Chun Fan Lee, K S Lawrence Wong, et al.
Alzheimer'S & Dementia (New York, N. Y.)|February 7, 2019
The <b>A</b>lzheimer's disease <b>THE</b>rapy with <b>NE</b>uroaid (<b>ATHENE</b>) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine-A randomized, double-blind, placebo-controlled trialChristopher L H Chen, Purabi Reang Sharma, Boon Yeow Tan, et al.
Cerebrovascular Diseases (Basel, Switzerland)|April 4, 2013
The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES)Christopher L H Chen, Kamran Ikram, Qiu Anqi, et al.
Stroke|October 19, 2013
Effects of MLC601 on early vascular events in patients after stroke: the CHIMES studyChristopher L H Chen, Narayanaswamy Venketasubramanian, Chun Fan Lee, et al.
Journal of Alzheimer'S Disease : JAD|July 16, 2014
Autoantibodies to GM1 and GQ1bα are not biological markers of Alzheimer's diseaseYumako Miura, Kazuki Miyaji, Yuek Ling Chai, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Stroke|October 6, 2023
Advances in Stroke: Brain Health in 2023Tatjana Rundek, Christopher L H Chen
Stroke|September 14, 2021
Vascular Brain HealthChristopher L H Chen, Tatjana Rundek
Cerebrovascular Diseases (Basel, Switzerland)|March 4, 2020
Frequency and Clinical Impact of Serious Adverse Events on Post-Stroke Recovery with NeuroAiD (MLC601) versus Placebo: The CHInese Medicine Neuroaid Efficacy on Stroke Recovery StudyNarayanaswamy Venketasubramanian, Rajesh B Moorakonda, Qingshu Lu, et al.
Stroke|December 3, 2015
Comparison Between the Original and Shortened Versions of the National Institutes of Health Stroke Scale in Ischemic Stroke Patients of Intermediate SeverityChun Fan Lee, Narayanaswamy Venketasubramanian, K S Lawrence Wong, et al.
Journal of the American Medical Directors Association|May 24, 2020
Psychometric Properties of the National Institute of Neurological Disorders and Stroke and Canadian Stroke Network Neuropsychological Battery in an Asian Older Adult SampleKimberly A Chew, Eddie J Y Chong, Christopher L H Chen, et al.
Journal of Evidence-Based Medicine|August 21, 2015
The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD)Narayanaswamy Venketasubramanian, Chun Fan Lee, K S Lawrence Wong, et al.
Alzheimer'S & Dementia (New York, N. Y.)|February 7, 2019
The <b>A</b>lzheimer's disease <b>THE</b>rapy with <b>NE</b>uroaid (<b>ATHENE</b>) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine-A randomized, double-blind, placebo-controlled trialChristopher L H Chen, Purabi Reang Sharma, Boon Yeow Tan, et al.
Cerebrovascular Diseases (Basel, Switzerland)|April 4, 2013
The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES)Christopher L H Chen, Kamran Ikram, Qiu Anqi, et al.
Stroke|October 19, 2013
Effects of MLC601 on early vascular events in patients after stroke: the CHIMES studyChristopher L H Chen, Narayanaswamy Venketasubramanian, Chun Fan Lee, et al.
Journal of Alzheimer'S Disease : JAD|July 16, 2014
Autoantibodies to GM1 and GQ1bα are not biological markers of Alzheimer's diseaseYumako Miura, Kazuki Miyaji, Yuek Ling Chai, et al.
Pageof 4